“…The current study suggests that T 4 , an inexpensive, toxicologically very well-defined hormone that has been systemically administered in clinical medicine for decades (Biondi and Wartofsky, 2014;Topliss and Soh, 2013) and is intracutaneously deiodinated to T 3 (van Beek et al, 2008), could serve in the treatment of skin conditions and pathologies connected with a decline in mitochondrial function (Boulton et al, 2015), intrinsic and extrinsic skin aging (Anderson et al, 2014; M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 7 Berneburg, 2008;Gilchrest, 2013;Glass et al, 2013;Grillon et al, 2012;Kaneko et al, 2012;Oyewole et al, 2014). Topical application of T 4 is expected to reduce the well-known adverse effects associated with elevated systemic TH levels (Kharlip and Cooper, 2009;Taylor et al, 2013;Walrand et al, 2014). Interestingly, topical T 3 has already been shown to promote murine skin wound healing and hair growth in vivo (Safer, 2012;Safer et al, 2005), while a topically applied TH analogue counteracted glucocorticoid-induced human skin atrophy (Yazdanparast et al, 2006).…”